Cancer-specific T cell receptor discovery using 150,000 clinical genomics samples

T cell receptors (TCRs) can enable detection and elimination of cancer cells via recognition of cancer-specific peptides presented on human leukocyte antigen (HLA). We speculated that shared cancer antigens could be recognized by recurrent (“public”) TCRs, which might be identifiable using statistical methods. Here, we identified public TCRs against therapeutically relevant targets via computational analysis of large-scale bulk RNA sequencing data obtained from routine clinical genomics testing. Using data from ∼150,000 patient tumor samples, we identified TCR chains that were associated with well-known cancer antigens, including human papillomavirus, mutated KRAS, and CT83. We devised methods for pairing enriched TCR-α and TCR-β chain sequences and validated 44 TCRs across nine peptide-HLA targets for antigen recognition, including potent cytotoxic TCRs. Our results suggest that public anticancer TCRs are common and may represent a new source for the development of cancer therapeutics.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2026-11-04
DOI
https://doi.org/10.1126/scitranslmed.aeh8192
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cancer-specific T cell receptor discovery using 150,000 clinical genomics samples

Matthew C. Funsten, Paul Fields, Amber Martin, Vikram R. Juneja et al.
Science Translational Medicine
Cancer Immunotherapy and Biomarkers
article

Cancer-specific T cell receptor discovery using 150,000 clinical genomics samples

Matthew C. Funsten, Paul Fields, Amber Martin, Vikram R. Juneja, Sebastian Newrzela, Benjamin P. Roscoe, Dinesh Manandhar, Stephanie LaHaye, Jared L. Dietze, Sandina Gnoth, Ekaterina Esaulova, Gavin M. Palowitch, Charles L. Dulberger, Christian Yee, Hannah I. Miller, Daniella Tatang, Rohit Vyasamneni, Mikhaylov Victor, Yuxin Hao, Fu Luo, Emily K. Jackson, Richard B. Gaynor, John R. Srouji, Michael Rooney, Maria Massaro, Yushu Joy Xie, Nicholas M. Ward, Tyler Nicholson
article en

Abstract

T cell receptors (TCRs) can enable detection and elimination of cancer cells via recognition of cancer-specific peptides presented on human leukocyte antigen (HLA). We speculated that shared cancer antigens could be recognized by recurrent (“public”) TCRs, which might be identifiable using statistical methods. Here, we identified public TCRs against therapeutically relevant targets via computational analysis of large-scale bulk RNA sequencing data obtained from routine clinical genomics testing. Using data from ∼150,000 patient tumor samples, we identified TCR chains that were associated with well-known cancer antigens, including human papillomavirus, mutated KRAS, and CT83. We devised methods for pairing enriched TCR-α and TCR-β chain sequences and validated 44 TCRs across nine peptide-HLA targets for antigen recognition, including potent cytotoxic TCRs. Our results suggest that public anticancer TCRs are common and may represent a new source for the development of cancer therapeutics.

Science Translational MedicineVol. 18(874)
Tempus Labs (United States) (US), BioNTech (Germany) (DE), BioNTech (United States) (US)
Openalex Percentile: Top 17%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon